{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:31:18Z","timestamp":1789705878002,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["223195\/Z\/21\/Z"],"award-info":[{"award-number":["223195\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.eclinm.2024.103036","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T13:54:25Z","timestamp":1737208465000},"page":"103036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)"],"prefix":"10.1016","volume":"80","author":[{"given":"Podjanee","family":"Jittamala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-8748","authenticated-orcid":false,"given":"William H.K.","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thundon","family":"Ngamprasertchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanaya","family":"Siripoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viravarn","family":"Luvira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Batty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phrutsamon","family":"Wongnak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisia M.","family":"Esper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro J.","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cintia","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando R.","family":"Ascencao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato S.","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najia K.","family":"Ghanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Callery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varaporn","family":"Kruabkontho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thatsanun","family":"Ngernseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaruwan","family":"Tubprasert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanassanan","family":"Madmanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanokon","family":"Suwannasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amornrat","family":"Promsongsil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borimas","family":"Hanboonkunupakarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kittiyod","family":"Poovorawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manus","family":"Potaporn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attasit","family":"Srisubat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bootsakorn","family":"Loharjun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter R.J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Qamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Momin","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Asim","family":"Beg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danoy","family":"Chommanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisouphanh","family":"Vidhamaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kesinee","family":"Chotivanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallika","family":"Imwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasithon","family":"Pukrittayakamee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen M.","family":"Dondorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.J.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6944-3008","authenticated-orcid":false,"given":"Mauro M.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Watcharapong","family":"Piyaphanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weerapong","family":"Phumratanaprapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2024.103036_bib1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.103036_bib2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0140-6736(22)00372-5","article-title":"The global COVID-19 treatment divide","volume":"10327","author":"Usher","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2024.103036_bib3","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1111\/bcp.15783","article-title":"Post-marketing safety concerns with nirmatrelvir: a disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System","volume":"9","author":"Zhuang","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eclinm.2024.103036_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(23)00493-0","article-title":"Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial","volume":"24","author":"Schilling","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eclinm.2024.103036_bib5","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-023-06649-6","article-title":"A\u00a0molnupiravir-associated mutational signature in global SARS-CoV-2 genomes","volume":"623","author":"Sanderson","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.eclinm.2024.103036_bib6","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1038\/s41380-021-01021-4","article-title":"Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study","volume":"26","author":"Hoertel","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.eclinm.2024.103036_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.33090","article-title":"Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants","volume":"4","author":"Oskotsky","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eclinm.2024.103036_bib8","first-page":"5882","article-title":"Antidepressant use and its association with 28-day mortality in inpatients with SARS-CoV-2: support for the FIASMA model against COVID-19","volume":"11","author":"Hoertel","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.eclinm.2024.103036_bib9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41398-022-01804-5","article-title":"Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study","volume":"12","author":"Hoertel","year":"2022","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.eclinm.2024.103036_bib10","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1192\/bjo.2021.1053","article-title":"Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort","volume":"8","author":"Clelland","year":"2022","journal-title":"BJPsych Open"},{"key":"10.1016\/j.eclinm.2024.103036_bib11","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial","volume":"324","author":"Lenze","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2024.103036_bib12","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2214-109X(21)00448-4","article-title":"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial","volume":"1","author":"Reis","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.eclinm.2024.103036_bib13","doi-asserted-by":"crossref","first-page":"667","DOI":"10.7326\/M22-3305","article-title":"Oral fluvoxamine with inhaled budesonide for treatment of early-onset COVID-19: a randomized platform trial","volume":"176","author":"Reis","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2024.103036_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad419","article-title":"The STOP COVID 2 study: fluvoxamine vs placebo for outpatients with symptomatic COVID-19, a fully remote randomized controlled trial","volume":"10","author":"Reiersen","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.eclinm.2024.103036_bib15","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1001\/jama.2023.23363","article-title":"Higher-dose fluvoxamine and time to sustained recovery in outpatients with COVID-19: the ACTIV-6 randomized clinical trial","volume":"24","author":"Stewart","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2024.103036_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2201662","article-title":"Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19","volume":"387","author":"Bramante","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.103036_bib17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/jama.2022.24100","article-title":"Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial","volume":"329","author":"McCarthy","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2024.103036_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijid.2023.06.018","article-title":"Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: open-label randomized controlled trial (EFFaCo study)","volume":"134","author":"Siripongboonsitti","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.eclinm.2024.103036_bib19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41380-021-01309-5","article-title":"The acid sphingomyelinase\/ceramide system in COVID-19","volume":"27","author":"Kornhuber","year":"2022","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.eclinm.2024.103036_bib20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/cbf.3789","article-title":"Acid sphingomyelinase (ASM) and COVID-19: a review of the potential use of ASM inhibitors against SARS-CoV-2","volume":"41","author":"Pauletto","year":"2023","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.eclinm.2024.103036_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.755600","article-title":"Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine shows antiviral activity against the novel variants in\u00a0vitro","volume":"12","author":"Fred","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eclinm.2024.103036_bib22","series-title":"WHO Model List of Essential Medicines - 23rd List","year":"2023"},{"key":"10.1016\/j.eclinm.2024.103036_bib23","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1038\/s41598-021-85049-0","article-title":"The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue","volume":"11","author":"Zimniak","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.eclinm.2024.103036_bib24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.12688\/f1000research.53275.1","article-title":"Fluoxetine pharmacokinetics and tissue distribution suggest a possible role in reducing SARS-CoV-2 titers","volume":"10","author":"Eugene","year":"2021","journal-title":"F1000 Research"},{"key":"10.1016\/j.eclinm.2024.103036_bib25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2024.103036_bib26","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/infdis\/jiae052","article-title":"Surrogate endpoints in pandemic preparedness","volume":"229","author":"de Grooth","year":"2024","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.eclinm.2024.103036_bib27","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2666-5247(23)00398-1","article-title":"Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: a systematic review and meta-analysis","volume":"5","author":"Elias","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.eclinm.2024.103036_bib28","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jac\/dkae045","article-title":"The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis","volume":"79","author":"Singh","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eclinm.2024.103036_bib29","article-title":"Pharmacometric assessment of the in\u00a0vivo antiviral activity of ivermectin in early symptomatic COVID-19","volume":"12","author":"Schilling","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.eclinm.2024.103036_bib30","article-title":"Clinical antiviral efficacy of remdesivir and casirivimab\/imdevimab against the SARS-CoV-2 Delta and Omicron variants","author":"Jittamala","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.eclinm.2024.103036_bib31","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/infdis\/jiad275","article-title":"Clinical antiviral efficacy of remdesivir in coronavirus disease 2019: an open-label, randomized controlled adaptive platform trial (PLATCOV)","volume":"228","author":"Jittamala","year":"2023","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.eclinm.2024.103036_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12879-023-08835-3","article-title":"Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial","volume":"24","author":"Luvira","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.eclinm.2024.103036_bib34","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1473-3099(24)00183-X","article-title":"Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)","volume":"24","author":"Wongnak","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eclinm.2024.103036_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00192-22","article-title":"Characterizing SARS-CoV-2 viral clearance kinetics to improve the design of antiviral pharmacometric studies","volume":"66","author":"Watson","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eclinm.2024.103036_bib36","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1473-3099(24)00254-8","article-title":"Identifying efficacious SARS-CoV-2 antivirals in a changing immune landscape","volume":"24","author":"Visser","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eclinm.2024.103036_bib38","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1214\/20-BA1221","article-title":"Rank-normalization, folding, and localization: an improved rhat for assessing convergence of MCMC (with discussion)","volume":"16","author":"Vehtari","year":"2021","journal-title":"Bayesian Anal"},{"key":"10.1016\/j.eclinm.2024.103036_bib39","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s11222-016-9696-4","article-title":"Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC","volume":"27","author":"Vehtari","year":"2017","journal-title":"Stat Comput"},{"key":"10.1016\/j.eclinm.2024.103036_bib40","article-title":"Do the selective serotonin reuptake inhibitor antidepressants fluoxetine and fluvoxamine reduce mortality among\u00a0patients with COVID-19?","volume":"11","author":"Hoertel","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eclinm.2024.103036_bib42","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"15","author":"Hammond","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.103036_bib43","first-page":"508","article-title":"CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: a systematic review","volume":"44","author":"Dorji","year":"2019","journal-title":"J\u00a0Clin Pharm Therapeut"},{"key":"10.1016\/j.eclinm.2024.103036_bib44","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41467-024-45641-0","article-title":"Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients","volume":"15","author":"Standing","year":"2024","journal-title":"Nat Commun"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024006151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024006151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T19:56:06Z","timestamp":1740858966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024006151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":41,"alternative-id":["S2589537024006151"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.103036","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.01.16.24301337","asserted-by":"object"}]},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.103036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103036"}}